Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.71 |
| ▸ | PLAU | P00749 | 2/20 | 0.62 |
| ▸ | PLG | P00747 | 1/20 | 0.62 |
| ▸ | PLAT | P00750 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174639 | 0.91 | NPC1 (0.74) | SMN1; SMN2TP53RAB9ANPC1MEN1 | |
| SCHEMBL4174870 | 0.90 | CYP1A2 (0.67) | SMN1; SMN2TP53PLAUPLGPLAT | |
| SCHEMBL13639753 | 0.84 | RXFP1 (0.62) | SMN1; SMN2PLAUPLGPLATRAB9A | |
| SCHEMBL6300804 | 0.80 | POLB (0.67) | SMN1; SMN2TP53PLAUPLGPLAT | |
| SCHEMBL4171948 | 0.79 | CYP2C8 (0.69) | SMN1; SMN2TP53RAB9ANPC1MEN1 | |
| SCHEMBL4172166 | 0.78 | SELL (0.59) | SMN1; SMN2TP53RAB9ANPC1MEN1 | |
| SCHEMBL4165226 | 0.78 | SELL (0.69) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL4167549 | 0.77 | CYP1A2 (0.67) | SMN1; SMN2TP53RAB9ANPC1MEN1 | |
| SCHEMBL13639737 | 0.77 | CYP1A2 (0.67) | SMN1; SMN2PLAUPLGPLATMEN1 | |
| SCHEMBL13964651 | 0.77 | ALDH1A1 (0.54) | SMN1; SMN2TP53PLAUPLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948146-B1 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-11-07 | — | — | EP | disclosed |
| EP-1948146-B1 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-11-07 | — | — | EP | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| EP-1948146-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | Revotar Biopharmaceuticals AG (DE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007039111-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039111-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | SELP, SELE, SELL | SMN1; SMN2 3347/4885TP53 1268/4885PLAU 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.